Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 6, 2016, Pages 934-940

  Liu, Chang Pan ^a,b,c,d   Shih, Shou Chuan ^a,b,d   Wang, Nai Yu ^a   Wu, Alice Y ^a,b   Sun, Fang Ju ^a,d   Chow, Shan Fan ^c   Chen, Te Li ^e,f   Yan, Tsong Rong ^c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c TATUNG UNIVERSITY   (Taiwan)

^d NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Acinetobacter baumannii, bacteremia; mortality; risk factors

Indexed keywords

CARBAPENEM; CEFTRIAXONE; COLISTIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA; CLONAL VARIATION; FEMALE; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MORTALITY RATE; MORTALITY RISK; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; RISK FACTOR; SEQUENCE ANALYSIS; TAIWAN; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; BACTEREMIA; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RESPIRATORY TRACT INFECTIONS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85006288781     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.10.006     Document Type: Article

References (35)

1. 1 Munoz-Price, L.S., Weinstein, R.A., Acinetobacter infection. N Engl J Med 358 (2008), 1271–1281.
2. 2 Gerner-Smidt, P., Tjernberg, I., Ursing, J., Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 29 (1991), 277–282.
3. 3 Nemec, A., Krizova, L., Maixnerova, M., Van der Reijden, T.J., Deschaght, P., Passet, V., et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus–Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol 162 (2011), 393–404.
4. 4 Peleg, A.Y., Seifert, H., Paterson, D.L., Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21 (2008), 538–582.
5. 5 Lee, N.Y., Chang, T.C., Wu, C.J., Chang, C.M., Lee, H.C., Chen, P.L., et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 61 (2010), 219–227.
6. 6 Chuang, Y.C., Sheng, W.H., Li, S.Y., Lin, Y.C., Wang, J.T., Chen, Y.C., et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 52 (2011), 352–360.
7. 7 Reinert, R.R., Low, D.E., Rossi, F., Zhang, X., Wattal, C., Dowzicky, M.J., Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007), 1018–1029.
8. 8 Perez, F., Hujer, A.M., Hujer, K.M., Decker, B.K., Rather, P.N., Bonomo, R.A., Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007), 3471–3484.
9. 9 Jean, S.S., Hsueh, P.R., Lee, W.S., Chang, H.T., Chou, M.Y., Chen, I.S., et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 33 (2009), 266–271.
10. 10 Centers for Disease Control, Nosocomial infection surveillance system. Centers for Disease Control, (eds.) Statistics of communicable diseases and surveillance report Republic of China 2010, 2011, Centers for Disease Control, Department of Health, Taiwan, R.O.C., 42–48.
11. 11 Sunenshine, R.H., Wright, M.O., Maragakis, L.L., Harris, A.D., Song, X., Hebden, J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13 (2007), 97–103.
12. 12 Sheng, W.H., Liao, C.H., Lauderdale, T.L., Ko, W.C., Chen, Y.S., Liu, J.W., et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 14 (2010), e764–e769.
13. 13 Playford, E.G., Craig, J.C., Iredell, J.R., Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 65 (2007), 204–211.
14. 14 Lemos, E.V., de la Hoz, F.P., Einarson, T.R., McGhan, W.F., Quevedo, E., Castaneda, C., et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 20 (2014), 416–423.
15. 15 Lee, N.Y., Wang, C.L., Chuang, Y.C., Yu, W.L., Lee, H.C., Chang, C.M., et al. Combination carbapenem–sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 27 (2007), 1506–1511.
16. 16 Kim, S.Y., Jung, J.Y., Kang, Y.A., Lim, J.E., Kim, E.Y., Lee, S.K., et al. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit. J Korean Med Sci 27 (2012), 939–947.
17. 17 Kim, Y.J., Kim, S.I., Hong, K.W., Kim, Y.R., Park, Y.J., Kang, M.W., Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci 27 (2012), 471–475.
18. 18 Nakwan, N., Chokephaibulkit, K., Carbapenem-resistant Acinetobacter baumannii bacteremia in neonates. Pediatr Infect Dis J, 32, 2013, 197.
19. 19 Thatrimontrichai, A., Apisarnthanarak, A., Chanvitan, P., Janjindamai, W., Dissaneevate, S., Maneenil, G., Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case–case–control study. Pediatr Infect Dis J 32 (2013), 140–145.
20. 20 Yang, Y.S., Lee, Y.T., Tsai, W.C., Kuo, S.C., Sun, J.R., Yang, C.H., et al. Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis. BMC Infect Dis 13 (2013), 1–7.
21. 21 Chen, T.L., Siu, L.K., Wu, R.C., Shaio, M.F., Huang, L.Y., Fung, C.P., et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 13 (2007), 801–806.
22. 22 Chang, H.C., Wei, Y.F., Dijkshoorn, L., Vaneechoutte, M., Tang, C.T., Chang, T.C., Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol 43 (2005), 1632–1639.
23. 23 Huang, S.T., Chiang, M.C., Kuo, S.C., Lee, Y.T., Chiang, T.H., Yang, S.P., et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 45 (2012), 356–362.
24. 24 Routsi, C., Pratikaki, M., Platsouka, E., Sotiropoulou, C., Nanas, S., Markaki, V., et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 38 (2010), 173–180.
25. 25 Le Hello, S., Falcot, V., Lacassin, F., Mikulski, M., Baumann, F., Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific. Scand J Infect Dis 42 (2010), 821–826.
26. 26 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. 2011, CLSI, Wayne, PA CLSI Document M100–S21.
27. OXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 44 (2006), 2974–2976.
28. 28 La Scola, B., Gundi, V.A., Khamis, A., Raoult, D., Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol 44 (2006), 827–832.
29. 29 Huang, L.Y., Chen, T.L., Lu, P.L., Tsai, C.A., Cho, W.L., Chang, F.Y., et al. Dissemination of multidrug-resistant, class 1 integron-carrying Acinetobacter baumannii isolates in Taiwan. Clin Microbiol Infect 14 (2008), 1010–1019.
30. 30 O'Grady, N.P., Alexander, M., Burns, L.A., Dellinger, E.P., Garland, J., Heard, S.O., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52 (2011), e162–e193.
31. 31 Karageorgopoulos, D.E., Falagas, M.E., Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8 (2008), 751–762.
32. 32 Falagas, M.E., Kopterides, P., Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64 (2006), 7–15.
33. 33 Lee, Y.T., Kuo, S.C., Yang, S.P., Lin, Y.T., Tseng, F.C., Chen, T.L., et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 55 (2012), 209–215.
34. 34 Badawy, A.A., Zaher, T.I., Sharaf, S.M., Emara, M.H., Shaheen, N.E., Aly, T.F., Effect of alternative antibiotics in treatment of cefotaxime resistant spontaneous bacterial peritonitis. World J Gastroenterol 19 (2013), 1271–1277.
35. 35 Poulikakos, P., Tansarli, G.S., Falagas, M.E., Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33 (2014), 1675–1685.